Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Irene Navarro Vicente, Antonio Solana-Altabella, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares Gil, Tamara Castaño, Jesús Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepcion, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal Toscano, Laura Lamarca, Mar Tormo, Cristina Gil, Mercedes Colorado, Manuel Barrios García, Matxalen Olivares Salaverri, Lisette Costilla-Barriga, Rebeca Rodriguez Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 319.

https://doi.org/10.1182/blood-2024-205172

Published: 2024

Journal Articles

Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 4328.

https://doi.org/10.1182/blood-2024-203076

Published: 2024

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Blood (2023) 142 (Supplement 1): 4234.

https://doi.org/10.1182/blood-2023-190296

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2023-180646

Published: 2023

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 2270–2272.

https://doi.org/10.1182/blood-2022-163159

Published: 2022

Journal Articles

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Blood (2022) 140 (Supplement 1): 3422–3424.

https://doi.org/10.1182/blood-2022-166639

Published: 2022

Journal Articles

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Blood (2022) 140 (Supplement 1): 9100–9102.

https://doi.org/10.1182/blood-2022-163016

Published: 2022

Journal Articles

Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain

Josep-Maria Ribera, Olga Garcia, Pau Montesinos, Rebeca Rodríguez-Veiga, María García-Fortes, Abelardo Barez Garcia, Itziar Oiartzabal, Jose A Gonzalez-Campos, Jose Angel Mendez Sanchez, Maite Zudaire, Lucia Villalon, Oriana López-Godino, Cristina Gil, Ana Vicent, Raquel Saldaña, Marta Valero, Anna Torrent, Jesus Maria Hernández-Rivas

Blood (2021) 138 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2021-148368

Published: 2021

Journal Articles

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Blood (2021) 138 (Supplement 1): 872.

https://doi.org/10.1182/blood-2021-147735

Published: 2021

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

Journal Articles

Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

Blood (2021) 138 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2021-150544

Published: 2021

Journal Articles

Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2021) 138 (Supplement 1): 1256.

https://doi.org/10.1182/blood-2021-150649

Published: 2021

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2021-150281

Published: 2021

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134296

Published: 2020

Journal Articles

Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-134651

Published: 2020

NARROW

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study)

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Results of the Compassionate Program of Inotuzumab Ozogamicin for Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia in Spain

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry

Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only